TEOXANE announces FDA Approval for three HA dermal fillers, RHA®2, RHA®3 and RHA®4 indicated for the correction of moderate to severe dynamic facial wrinkles and folds.
Geneva, Switzerland, October 19th 2017 –Teoxane Laboratories, a global leader in Hyaluronic Acid dermal fillers, are pleased to announce that it has received US Food and Drug Administration (FDA) approval for 3 HA dermal fillers, RHA®2, RHA®3 and RHA®4 for the correction of moderate to severe dynamic facial wrinkles and folds (NLF) in adults aged 22 years or older.
Teoxane’s Founder and CEO Valerie Taupin said “ Since its inception in 2003, the foundations of the company have been based on integrated Research & Development. Today we are delighted with the news of the FDA approval of RHA®2, RHA®3 and RHA®4 for sale in the US market. This further reinforces our commitment to delivering science-based, high-quality HA dermal fillers to the Global market”.